The Vascular Disease of Diabetic Kidney Disease

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Diabetic kidney disease (DKD) is associated with a higher incidence of cardiovascular disease (CVD).
• The global prevalence of diabetes and DKD is increasing.
• Factors like insulin resistance, hyperglycemia, and hypertension contribute to CVD pathogenesis in type-2 diabetes.

Purpose of the Study:

• To explore arterial stiffening as a mediator between diabetes and cardiac dysfunction.
• To discuss the cardiovascular and kidney protective effects of sodium-glucose cotransporter type-2 inhibitors.

Main Methods:

• This study is a narrative review.
• Analysis of existing literature on arterial stiffening, diabetes, and cardiovascular outcomes.
• Review of evidence on sodium-glucose cotransporter type-2 inhibitors' effects.

Main Results:

• Arterial stiffening is identified as a key vascular mechanism linking diabetes to cardiac dysfunction.
• Sodium-glucose cotransporter type-2 inhibitors demonstrate significant cardiovascular and nephroprotective benefits.

Conclusions:

• Arterial stiffening plays a crucial role in the development of cardiac dysfunction in diabetic patients.
• Sodium-glucose cotransporter type-2 inhibitors represent a promising therapeutic strategy for managing cardiovascular and renal complications in DKD.